Back

ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia

28 August 2026 (11:35 - 11:45)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Sotirios Tsimikas

University of California San Diego, La Jolla (United States of America)

5 More presentations in this session

Presentation thumbnail
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
Professor S. Zhong (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Doctor D. Bhatt (New York City, US)
Abstract Slides
Presentation thumbnail
Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials
Doctor E. Stroes (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III
Doctor P. C Revaiah (New York, US)
Abstract Slides

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:35 CET
You may be interested in
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020
thumbnail
Congress Presentation
Long-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia
28 August 2026
thumbnail
Congress Presentation
Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis
24 April 2026
thumbnail
Congress Presentation
Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources